OTCM
DRHNF
Market cap50mUSD
Sep 21, Last price
51.60
Name
Dr Hoenle AG
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
1.70%
Rev. 5Y
-0.04%
Div Yld LY
—
Div Yld TTM
—
Revenues
94m
-5.11%
Net income
-3m
L-76.15%
CFO
5m
-8.43%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Dr. Hönle AG is a global provider specializing in industrial ultraviolet (UV) technologies and related systems, with operations spanning Germany and international markets. The company organizes its business into three main segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives division develops industrial bonding solutions for critical applications within sectors such as consumer electronics, medical technology, optics and opto-electronics, the automotive industry, and glass processing. Its Equipment & Systems segment focuses on developing solutions for the efficient drying of inks and coatings, the precise curing of adhesives and plastics, comprehensive surface disinfection, and advanced solar simulation. Lastly, the Glass & Lamps division manufactures quartz glass tubing and rods, which are vital for the lamp, automotive, semiconductor, and fiber optic cable industries, alongside producing specialized lamps utilized for water purification and the drying of various coatings and adhesives. Founded in 1976, Dr. Hönle AG is headquartered in Munich, Germany.
Related entities
Subsidiaries (2)
PANACOL-ELOSOL GmbH
uv-technik Speziallampen GmbH
Key people
Independent Chairman of the Supervisory Board · since 2024
Markus Arendt
Chairman of the Management Board, Chief Executive Officer · since 2024
Robert Stark
Chief Financial Officer, Member of the Management Board · since 2024
Niklas Friedrichsen
Independent Member of the Supervisory Board · since 2024
Bernhard Gimple
Independent Vice Chairman of the Supervisory Board · since 2024
Imke Libon
Independent Member of the Supervisory Board · since 2021
Melanie Ott
Independent Member of the Supervisory Board · since 2024
Headquarters & legal address
Nicolaus-Otto-Straße 2
Gilching, BY 82205
DE
Gilching, BY 82205
DE
Previous name
Dr. Hönle Aktiengesellschaft
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||